Planet Microcap Podcast | Microcap Investing Strategies

My guests on the show today is Craig Mull (CEO), Bryan Jacobs (President) of Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF). Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.   On July 29, 2024, Cipher announced that it acquired the global product rights for Natroba, as well as the commercial sales team in the US for $89.5 million from ParaPRO. Following this acquisition, the largest in the company's history, I invited on the management team to learn more about: History of Cipher and how they've narrowed their focus on providing dermatology products for the under-18 consumer What the competitive landscape looks like Acquisition of Natroba and what that me